Development of a novel pharmacologic strategy to activate normal pathways of differentiation in melanoma

National Center For Advancing Translational Sciences

Investigators

Abstract

During this period, the NCGC worked to validate and characterize previously identified screening hits in the primary melanoma assay. A focused collection of approximately 500 small molecules targeting a broad range of cellular mechanisms was screened, and four active compounds that increased melanoma antigen expression leading to enhanced IFN production were identified and validated using follow-up assays. These four compounds may provide a basis for enhanced immune recognition and to design novel therapeutic approaches for patients with BRAF mutant melanoma resistant to ACT because of antigen downregulation.